retatrutide eli lilly press release 2024 2025 touts strong results of new experimental weight loss drug I Answered Retatrutide's Biggest Unanswered
Description
Clinical trial data do not apply: Eli Lilly's investigational Retatrutide has been studied in human clinical trials, and adverse event data from those trials are published [3]
doi: 10.1210/endrev/bnaa032 [DOI] [PMC free article] [PubMed] [Google Scholar] 63.Christensen M, Vedtofte L, Holst JJ, et al
Adverse effects Besides nausea which was more frequent in the GLP-1RA group (40 vs 4%), there was no difference in the occurrence of adverse effects
Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review
Med spa clients in 2026 arrive informed, comparison-shopping, and ready to judge the full client experience as much as the treatment itself
